SCHEMBL870166

SCHEMBL870166

CN1CCN(CC(=O)NC2CCC(n3c(=O)c4cc(F)cnc4n(-c4cccc(-c5ccc(CN6CCCN(C)CC6)cc5)c4)c3=O)CC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR1B P47901 2/20 0.44
PDE4B Q07343 5/20 0.38
SIGMAR1 Q99720 1/20 0.38
CHKA P35790 3/20 0.37
AXL P30530 3/20 0.37
FLT3 P36888 3/20 0.37
TYRO3 Q06418 3/20 0.37
MERTK Q12866 3/20 0.37
DYRK1A Q13627 2/20 0.36
GSK3B P49841 1/20 0.36
SLC2A1 P11166 2/20 0.36
WNT1 P04628 1/20 0.36
ADRB2 P07550 1/20 0.36
MAP4K4 O95819 1/20 0.35
NTRK1 P04629 1/20 0.35
MELK Q14680 1/20 0.35
NTRK3 Q16288 1/20 0.35
NTRK2 Q16620 1/20 0.35
SLK Q9H2G2 1/20 0.35
TNIK Q9UKE5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL870165 1.00 AVPR1B (0.44) AVPR1BPDE4BSIGMAR1CHKAAXL
SCHEMBL870450 0.99 AVPR1B (0.43) AVPR1BPDE4BSIGMAR1CHKAAXL
SCHEMBL870449 0.99 AVPR1B (0.43) AVPR1BPDE4BSIGMAR1CHKAAXL
SCHEMBL3030807 0.93 AVPR1B (0.41) AVPR1BPDE4BCHKAAXLFLT3
SCHEMBL3030814 0.93 AVPR1B (0.41) AVPR1BPDE4BCHKAAXLFLT3
SCHEMBL3019156 0.93 AVPR1B (0.39) AVPR1BPDE4BSIGMAR1CHKAAXL
SCHEMBL8170394 0.93 AVPR1B (0.39) AVPR1BPDE4BSIGMAR1CHKAAXL
SCHEMBL870300 0.93 AVPR1B (0.39) AVPR1BPDE4BCHKAAXLFLT3
SCHEMBL870299 0.93 AVPR1B (0.39) AVPR1BPDE4BCHKAAXLFLT3
SCHEMBL870597 0.91 PDE4B (0.38) AVPR1BPDE4BCHKAAXLFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2106396-B1 CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS ALCON RES LTD (US) 2014-09-24 EP disclosed
US-20120077801-A1 Chemical Compounds 637 ALCON RESEARCH, LTD. 2012-03-29 US disclosed
US-20100204203-A1 Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors ALCON RESEARCH, LTD. 2010-08-12 US disclosed
US-20090124596-A1 Chemical Compounds 637 ALCON RESEARCH, LTD. 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077801-A1 Chemical Compounds 637 PDE4A, PDE4B, PDE3B AVPR1B 1234/4885PDE4B 2/4885SIGMAR1 3813/4885
US-20090124596-A1 Chemical Compounds 637 PDE4A, PDE4B, PDE3B AVPR1B 1234/4885PDE4B 2/4885SIGMAR1 3813/4885
US-20100204203-A1 Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors PDE4A, PDE4B, PDE5A AVPR1B 1852/4885PDE4B 2/4885SIGMAR1 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.